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IMPORTANCE Behavioral therapy and cognitive-behavioral therapy (CBT) programs targeting
a single class of problems have not been widely implemented. The population of youths with
common mental health problems is markedly undertreated.
OBJECTIVE To determine the effectiveness of a new transdiagnostic CBT program (Mind My
Mind [MMM]) compared with management as usual (MAU) in youths with emotional and
behavioral problems below the threshold for referral to mental health care.
DESIGN, SETTING, AND PARTICIPANTS This pragmatic, multisite, randomized clinical trial of
MMM vs MAU was conducted from September 7, 2017, to August 28, 2019, including 8 weeks
of postintervention follow-up, in 4 municipalities in Denmark. Consecutive help-seeking
youths were randomized (1:1) to the MMM or the MAU group. Main inclusion criteria were age
6 to 16 years and anxiety, depressive symptoms, and/or behavioral disturbances as a primary
problem. Data were analyzed from August 12 to October 25, 2019.
INTERVENTIONS The MMM intervention consisted of 9 to 13 weekly, individually adapted
sessions of manualized CBT delivered by local psychologists. The MAU group received 2 care
coordination visits to enhance usual care.
MAIN OUTCOMES AND MEASURES The primary outcome was change in mental health
problems reported by parents at week 18, using the Strengths and Difficulties Questionnaire
(SDQ) Impact scale (range, 0-10 points, with higher scores indicating greater severity of
distress and impairment). Primary and secondary outcomes were assessed in the
intention-to-treat population at week 18. Maintenance effects were assessed at week 26.
RESULTS A total of 396 youths (mean [SD] age, 10.3 [2.4] years; 206 [52.0%] boys) were
randomized to MMM (n = 197) or MAU (n = 199), with primary outcome data available in 177
(89.8%) and 167 (83.9%), respectively, at 18 weeks. The SDQ Impact score decreased by 2.34
points with MMM and 1.23 with MAU, from initial scores of 4.12 and 4.21, respectively
(between-group difference, 1.10 [95% CI, 0.75-1.45]; P < .001; Cohen d = 0.60). Number of
responders (1-point reduction in SDQ Impact score) was greater with MMM than with MAU
(144 of 197 [73.1%] vs 93 of 199 [46.7%]; number needed to treat, 4 [95% CI, 3-6]).
Secondary outcomes indicated statistically significant benefits in parent-reported changes of
anxiety, depressive symptoms, daily functioning, school attendance, and the principal
problem. All benefits were maintained at week 26 except for school attendance.
CONCLUSIONS AND RELEVANCE In this randomized clinical trial, the scalable transdiagnostic
cognitive-behavioral intervention MMM outperformed MAU in a community setting on
multiple, clinically relevant domains in youth with emotional and behavioral problems.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03535805
JAMA Psychiatry. doi:10.1001/jamapsychiatry.2020.4045
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M ental health disorders constitute the largest diseaseburden among children and adolescents (herein re-ferred to as youths), and 50% of mental disorders be-
gin before 14 years of age.1,2 Youths with mild to moderate
symptoms of anxiety, depression, or behavioral disturbances
have an increased risk of adverse adult outcomes.3 Evidence
suggests that cognitive-behavioral therapies (CBTs) are effec-
tive for the indicated prevention and treatment of childhood
anxiety,4-6 depression,7-9 and behavioral difficulties.10,11 Nev-
ertheless, access to evidence-based prevention and treat-
ment interventions is limited, because those interventions
available are rarely used routinely in clinical practice.12,13 This
knowledge-practice gap requires bridging by pragmatic trials
testing the real-world implementation of scalable interven-
tions for common mental health problems among youths.12,14
The transdiagnostic Modular Approach to Therapy for Chil-
dren (MATCH) targets the most common mental health prob-
lems in youth.15 Two cluster-randomized clinical trials dem-
onstrated the benefits of the MATCH manual (Child STEPs)
compared with disorder-specific CBT and/or usual care on
symptoms 1 and 2 years after enrollment,15,16 with no effects
on functioning16 but reduced auxiliary service use in treat-
ment completers.17 However, the only individual-level ran-
domized clinical trial (RCT) of the Child STEPs found no su-
periority compared with usual care.18 More research is therefore
needed to investigate the feasibility and effectiveness of trans-
diagnostic, modular interventions for large-scale implemen-
tation of evidence-based treatments for youth.
We developed a new transdiagnostic CBT program for in-
dicated prevention and early treatment of youth problems be-
low the threshold for psychiatric referral. Our program (Mind
My Mind [MMM]) consisted of manualized CBT with mod-
ules, worksheets, play materials, case examples, and flow-
charts guiding individually adapted treatment; standardized
procedures for identifying/monitoring the target problem; and
education/supervision of psychologists using video observa-
tion–based feedback. A feasibility RCT (152 participants, ran-
domized 3:1) of MMM vs management as usual (MAU) in 4 mu-
nicipalities in Denmark showed acceptability and feasibility and
provided data for sample size estimation.19 The present de-
finitive RCT evaluated the effectiveness of MMM vs MAU.
We hypothesized that the parent-reported impact of men-
tal health problems would be significantly improved for youth
receiving MMM vs MAU after the 17-week intervention. The
secondary objectives were comparing the effectiveness of
MMM vs MAU on parent-, self-, and teacher-reported out-
comes of psychopathology, daily functioning, school atten-
dance, health-related quality of life, and potential harms at
weeks 18 (after the 17-week MMM intervention) and 26.
Methods
Study Design
The MMM study was a pragmatic, open-label, analyst-
masked, parallel, 2-arm, randomized clinical superiority trial
of MMM vs MAU for help-seeking youths with emotional and
behavioral problems. The trial was conducted in the Educa-
tional-Psychological Advisory Services in 4 sociodemographi-
cally diverse municipalities in Denmark (Vordingborg,
Næstved, Helsingør, and Holstebro). A copy of the trial proto-
col is available in Supplement 1. The trial conduct was over-
seen by a steering committee (also acting as the data and safety
monitoring board) with representatives from Danish child and
adolescent mental health services, municipalities, and the non-
governmental organization responsible for the program’s
implementation (Supplement 1 and eMethods 1 in Supple-
ment 2). The trial was approved by the scientific ethics com-
mittee, and the data management and protection complied
with the European Union General Data Protection Regula-
tion. Written informed consent signed by the legal guardians
was provided for all the participants. There were no changes
to trial methods after the trial commenced, and no data were
analyzed before study completion and database lock. This
study followed the Consolidated Standards of Reporting Trials
(CONSORT) reporting guideline.
Participants
Participants were recruited with help from local teachers,
school health nurses, psychologists, general practitioners, and
parents. Information was published online on school in-
tranets and municipality websites and handed to the local pro-
fessionals. Youth and parents contacted the Educational-
Psychological Advisory Service to sign up for assessment of
eligibility. No formal referral was required.
A 2-stage standardized screening of help-seeking youths
was implemented in the municipalities to identify eligible study
participants. The first stage used web-based questionnaires,
including the Strengths and Difficulties Questionnaire (SDQ),20
and an algorithm combining parent-reported scores of emo-
tional and behavioral problems and functional impairments
to identify youth requiring care (inclusion criteria). In the sec-
ond stage, youths underwent a semistructured, psychopatho-
logical interview to screen for developmental and mental dis-
orders. Finally, the most important problem for which parents
and youths wanted help was identified. This top problem was
recorded using their own words,21 and the problem severity
was scored from 1 to 10, with 10 indicating greatest severity.
Inclusion criteria consisted of (1) age of 6 to 16 years and
in compulsory school; (2) anxiety symptoms, depressive symp-
toms, and/or behavioral disturbances as top problem; and (3)
Key Points
Question Can a transdiagnostic modular cognitive-behavioral
therapy (CBT) program outperform management as usual for
youth with emotional and behavioral problems?
Findings In this randomized clinical trial of 396 youths aged 6 to
16 years, the parent-reported functional impairment was
significantly reduced for youth allocated to transdiagnostic
modular CBT compared with management as usual. Key secondary
outcomes also indicated a broad range of benefits.
Meaning This pragmatic study adds to the growing evidence that
the wide-scale implementation of transdiagnostic modular CBT in
nonspecialist care settings provides timely indicated prevention
and quality care for help-seeking youth.
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parent-reported SDQ Total Difficulties score of at least 14, Emo-
tional Problems score of at least 5, and/or Conduct Problems
score of at least 3, combined with an Impact score of at least 1
(ie, cutoff for 90th percentile of mental health problems in the
general age-matched population).22 Exclusion criteria con-
sisted of (1) prior clinical diagnosis of any developmental or
mental disorder; (2) signs of intellectual disability or severe
mental disorder, including autism-spectrum disorder, atten-
tion-deficit/hyperactivity disorder, psychotic disorder, eat-
ing disorder, obsessive-compulsive disorder, repeated self-
harm, or alcohol or psychoactive drug abuse; (3) youth or
parents unable to participate in weekly sessions; and (4) par-
ticipation in the prior feasibility study (Supplement 1). Thus,
we included help-seeking youths with emotional and behav-
ioral problems that were above the 90th percentile in the gen-
eral population of youth and still below the threshold for re-
ferral to specialized treatment in the child and adolescent
mental health services.
Randomization and Masking
The participants were randomized 1:1 to MMM vs MAU via cen-
tralized, computer-generated allocation sequences with per-
muted block sizes, stratified by geographical region (2 strata),
age (6-10 or 11-16 years), and the top problem (anxiety, depres-
sive symptoms, or behavioral problems). The Data and Docu-
mentation division in Corporate Quality–Central Denmark Re-
gion (Defactum) managed the online randomization and data-
entry system and kept the person identification lists separated
from the researchers. Defactum had no role in data analyses.
Because of the nature of the interventions, only the evalua-
tors and analysts were masked to group allocation.
Interventions
The MMM interventions consisting of 9 to 13 weekly sessions
were developed based on a systematic literature search
(eMethods 2 and 3 in Supplement 2), from which we distilled
50 CBT methods/techniques from evidence-based programs
targeting anxiety, depression, or behavioral disturbances as
single disorders. The methods/techniques were organized into
35 problem-specific or generic modules. Flowcharts describe
the sequencing and dosing of modules depending on the top
problem and possibilities for flexible adaptations to the indi-
vidual co-occurring problems (eFigures 1-3 in Supplement 2).
In case of behavioral problems, the main course was parent
management training (ages 6-13 years) or youth training of so-
cial, communicative, and adaptive skills. All parents were en-
gaged as coagents of change. The MMM intervention was com-
pleted within 17 weeks, followed by a booster session after 4
Figure 1. CONSORT Diagram of Participant Flow Through the Trial
573 Patients assessed for eligibility 177 Excluded
95 Did not meet ≥1 of the criteria for inclusion
75 Below threshold (SDQ cutoff)
7 Excluded due to unknown reasons
30 Parents did not want their child to
participate
14 Impairment, severe learning difficulties, or
other special needs
8 A prior diagnosis of any developmental or
mental disorder
8 The child and/or parents were unable to
participate in weekly sessions
2 Not aged 6 to 16 y and in 0 to 9th grade
1 Parents did not understand and speak
Danish sufficiently to participate in the
treatment
52 Indications that the child may have a severe
mental disorder
51 Top problem not in the domains of anxiety, 
depressive symptoms, and behavioral
problems
197 Randomized to MMM
196 Started MMM
199 Randomized to MAU
199 Started MAU
177 Responded to primary outcome
14 Discontinued
6 Missing at week 18 but




179 Responded to primary outcome
(including 6 who did not respond
at 18 wk)
158 Responded to primary outcome
(including 4 who did not respond
at 18 wk)
167 Responded to primary outcome
28 Discontinued
4 Missing at week 18 but







randomization, and 18- and 26-week
follow-up.
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weeks. The MMM training was provided by 24 psychologists
(22 [91.7%] female; mean [SD] age, 39.5 [10.8] years) who were
appointed by their local leader. Seventeen psychologists
(70.8%) reported prior experience with nonmanualized CBT;
3 (12.5%) had a formal CBT education. The therapists re-
ceived 1 week of training in the MMM treatment manual fol-
lowed by weekly online individual (75%) or live group (25%)
consultations with a local supervisor. The supervision pro-
cesses had input from the video recordings of sessions and the
online feedback from parents’ and youths’ top-problem scores.
The therapists and their supervisors were offered three 1-day
methodology courses and three 2-day booster trainings dur-
ing the study period.
The youth and parents in the MAU group were offered 2
care visits to help coordinate usual care in the municipality
(weeks 2 and 17). The MAU condition varied, because the
youths could receive counseling, pedagogical advice, net-
work meetings, educational support, or psychological treat-
ment of various forms, either publicly or privately funded, or
no further treatment (eMethods 4 in Supplement 2).
Measures and Outcomes
Baseline assessments were performed using standardized on-
line questionnaires to the youth, the parents, and the pri-
mary schoolteacher, including the Development and Well-
being Assessment questionnaires and interviews.23 The
Development and Well-being Assessment reports were rated
by senior consultants to determine mental disorders accord-
ing to the DSM-IV and DSM-5.
The primary outcome was the parent-reported change in
the impact of mental problems at end of treatment (week 18),
using the SDQ Impact scale from the Impact supplement. The
5-item SDQ Impact scale (range, 0-10)20 evaluates the impact
of mental health problems on a child’s distress and function-
ing in home life, friendships, classroom learning, and leisure
activities. The SDQ Impact scale has demonstrated good
Table 1. Baseline Characteristics of the Participants in the ITT Population
Characteristic
Study groupa
MMM (n = 197) MAU (n = 199) All (N = 396)
Demographic
Girls 90 (45.7) 100 (50.3) 190 (48.0)
Age, mean (SD), y 10.3 (2.43) 10.3 (2.32) 10.3 (2.37)
Age group, y
6-10 109 (55.3) 105 (52.8) 214 (54.0)
11-16 88 (44.7) 94 (47.2) 182 (46.0)
Region
Holstebro-Helsingør 95 (48.2) 96 (48.2) 191 (48.2)
Vordingborg-Næstved 102 (51.8) 103 (51.8) 205 (51.8)
Principal domain of problems
Anxiety 114 (57.9) 117 (58.8) 231 (58.3)
Depressive symptoms 31 (15.7) 33 (16.6) 64 (16.2)
Behavioral problems 52 (26.4) 49 (24.6) 101 (25.5)
Developmental delays
Language 30 (15.2) 26 (13.1) 56 (14.1)
Any otherb 62 (31.5) 48 (24.1) 110 (27.8)
School absenteeism >4 wk last year 33 (16.8) 39 (19.6) 72 (18.2)
No. of DSM-IV/DSM-5 mental disorders based on DAWBA
Anxiety disorder 102 (51.8) 118 (59.3) 220 (55.6)
Depressive disorder 25 (12.7) 33 (16.6) 58 (14.6)
Behavioral disorder 50 (25.4) 47 (23.6) 97 (24.5)
Neurodevelopmental disorder 25 (12.7) 32 (16.1) 57 (14.4)
Any disorder 153 (77.7) 164 (82.4) 317 (80.1)
Comorbidity, ≥2 disorders 45 (22.8) 57 (28.6) 102 (25.8)
Physical illness (asthma, diabetes, eczema, epilepsy, other) 34 (17.3) 37 (18.6) 71 (17.9)
Living arrangement
Both parents 126 (64.0) 122 (61.3) 248 (62.6)
Single parent 32 (16.2) 41 (20.6) 73 (18.4)
Other/reconstituted family 39 (19.8) 36 (18.1) 75 (18.9)
(continued)
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psychometric properties for capturing the functional im-
pacts of emotional and behavioral problems in youths20,24 and
for estimating the risk of concurrent and future disorder,25 ser-
vice use,24 and impairments.26
The key secondary outcomes at week 18 were changes
in (1) anxiety (Spence Children’s Anxiety Scale,27 parent-
reported), (2) depressive symptoms (Mood and Feelings
Questionnaire,28 parent-reported), (3) daily child function-
ing (Weiss Functional Impairment Rating Scale,29 parent-
reported), (4) school attendance (proportion of school days
attended within the last 4 weeks, parent-reported), (5) top-
problem score (ideographic measure, parent-reported;
range, 1-10),21 quality of life (KIDSCREEN-27),30 subscales
for (6) physical well-being and (7) psychological well-being
(child-reported), behavioral problems with the (8) Eyberg
Child Behavior Inventory intensity score31 (parent-reported)
and (9) Eyberg Child Behavior Inventory problem score31
(parent-reported) subscales, (10) total emotional and
behavioral problems (SDQ Total Difficulties sc ale,
parent-reported),20 (11) parent-reported response (SDQ
Impact score reduction ≥1 point), and (12) parent-reported
remission (SDQ algorithm scores below inclusion cutoff).
We also explored changes in outcomes from baseline to
week 26 (8 weeks after the MMM intervention’s cessation)
with MMM vs MAU. The exploratory outcomes included the
SDQ Impact and SDQ Total Difficulties scales scored by
schoolteachers, child-reported outcomes (aged 11-16 years
for SDQ, aged 8-16 years for Spence Children’s Anxiety Scale
and Mood and Feelings Questionnaire), satisfaction, mea-
sured with the Experience of Service Questionnaire,32 and
parental stress in role functioning, measured with the
Parental Stress Scale.33 All outcomes were assessed at weeks
Table 1. Baseline Characteristics of the Participants in the ITT Population (continued)
Characteristic
Study groupa
MMM (n = 197) MAU (n = 199) All (N = 396)
Parent registered as informant
Mother 169 (85.8) 173 (86.9) 342 (86.4)
Father 28 (14.2) 26 (13.1) 54 (13.6)
Mother’s highest educational level
Elementary school (9-10 y) 11 (5.6) 15 (7.5) 26 (6.6)
High school/vocational (11-14 y) 49 (24.9) 63 (31.7) 112 (28.3)
Bachelor and above (15-17 y) 116 (58.9) 100 (50.3) 216 (54.5)
Higher education (≥17 y) 21 (10.7) 21 (10.6) 42 (10.6)
Immigration history of parentsc
2 Born in Denmark 182 (92.4) 176 (88.9) 358 (90.6)
1 Not born in Denmark 14 (7.1) 17 (8.6) 31 (7.8)
2 Not born in Denmark 1 (0.5) 5 (2.5) 6 (1.5)
No. of children in the household
Index child only 23 (11.7) 23 (11.6) 46 (11.6)
2 11 (5.6) 119 (59.8) 230 (58.1)
≥3 63 (32.0) 57 (28.6) 120 (30.3)
Mother’s self-reported mental health problems
Anxiety 10 (5.1) 27 (13.6) 37 (9.3)
Depression 111 (56) 31 (15.6) 42 (10.6)
Other 15 (7.6) 26 (13.1) 41 (10.4)
Both parents had mental health problems 5 (2.5) 11 (5.5) 16 (4.0)
Primary outcome measure, mean (SD)
SDQ Impact scale score (parent-reported)c,d 4.12 (2.34) 4.21 (2.43) 4.16 (2.39)
Key secondary outcome measures, mean (SD)
Anxiety (SCAS score [parent-reported])e 26.69 (15.65) 30.01 (15.35) 28.36 (15.57)
Depressive symptoms (MFQ score [parent-reported])f 16.22 (11.46) 17.34 (11.23) 16.78 (11.34)
Level of daily functioning (WFIRS score [parent-reported])g 31.13 (15.48) 31.19 (13.89) 31.16 (14.69)
School attendance (parent-reported)h 0.87 (0.22) 0.86 (0.22) 0.86 (0.22)
Top-problem score (parent-reported) 7.22 (1.78) 7.41 (1.74) 7.32 (1.76)
KIDSCREEN-27 score (self-reported), mean (SD), t valuei
Physical Well-being scale 45.58 (9.98) 43.22 (10.31) 44.40 (1.20)
Psychological Well-being scale 44.94 (10.64) 42.96 (8.40) 43.95 (9.62)
Behavioral problems (ECBI [parent-reported]), mean (SD)
Intensity scorej 107.33 (30.87) 107.70
(29.72)
107.52 (30.26)
Problem scorek 11.01 (7.46) 10.97 (7.26) 10.99 (7.35)
Emotional and behavioral problems (SDQ Total Difficulties
score [parent-reported])l
15.99 (5.25) 16.11 (5.49)c 16.06 (5.36)
Abbreviations: DAWBA, Development
and Well-being Assessment; ECBI,
Eyberg Child Behavior Inventory; ITT,
intention-to-treat; MAU, management
as usual; MFQ, Mood and Feelings
Questionnaire; MMM, Mind My Mind;
SCAS, Spence Children’s Anxiety Scale;
SDQ, Strengths and Difficulties
Questionnaire; WFIRS, Weiss
Functional Impairment Rating Scale.
a Unless otherwise indicated, data are
expressed as number (percentage)
of patients. Percentages have been
rounded and may not total 100.
b Includes motor, social
communication, and learning
difficulties.
c One participant in the MAU group
had missing data.
d Scores range from 0 to 10, with
higher scores indicating greater
severity of distress and impairment.
e Scores range from 0 to 114, with
higher scores indicating greater
severity of anxiety.
f Scores range from 0 to 68, with
higher scores indicating greater
severity of depressive symptoms.
g Scores range from 0 to 150, with
higher scores indicating more
functional impairment.
h Indicates percentage of school days
in the last 4 weeks (range, 0-100).
i Determined using the
health-related quality of life, with 5
dimensions, of which we used the
Physical Well-being and
Psychological Well-being scales.
j Scores range from 36 to 252, with
higher scores indicating greater
intensity of behavioral problems.
k Scores range from 0 to 36, with
higher scores indicating more
behavioral problems.
l Scores range from 0 to 40, with
higher scores indicating greater
severity of general
psychopathology.
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0, 18, and 26. Moreover, the SDQ Impact scale and top prob-
lem scale were scored biweekly until week 18. The parents
reported all service use.
Potential Harms
We assessed harms at weeks 18 and 26, defined by 2 binary
composite scores (Supplement 1): (1) suicidality and negative
cognitions (using 8 self-reported questions from the Mood and
Feelings Questionnaire) and (2) poor quality of family rela-
tionships, free time, and friendships (using 9 self-reported
questions from KIDSCREEN-27). For both composite scores,
we applied the following rule: Harm was present if at least 1
question received a high score of 2 without an identical score
at baseline. Professionals could report adverse events (with-
out prespecified definitions) to the steering committee. Fi-
nally, all the children were followed up in Danish national reg-
istries for mortality.
Statistical Analyses
Data were analyzed from August 12 to October 25, 2019. We
designed the study with 90% power to detect a minimally
relevant group difference of 1.0 point on the parent-
reported SDQ Impact scale. With a 2-sided α = .05 and an SD
of 2.7 (based on the feasibility trial19), follow-up data on at
least 308 youths were required. We included 396 youths to
allow for as much as 22% attrition, based on experiences
from the feasibility trial. The primary and key secondary
continuous outcomes were analyzed according to the
intention-to-treat population using repeated-measures lin-
ear mixed models (ie, missing data were handled implicitly),
including a factor for treatment group (2 levels) and time (9
levels), the interaction between both, and adjustments for
baseline value and stratification factors.34 The least-squares
means with 95% CIs were estimated and subsequently con-
verted into Cohen effect sizes for interpretation. The
responder indices were analyzed using logistic regression
models, including a factor for group and adjustment for
stratification factors, and conservatively assuming missing
data to be from nonresponders. Odds ratios with 95% CIs
were estimated and converted into approximate risk ratios,
and numbers needed to treat (NNT) were calculated.
To explore the results’ robustness for the primary and
key secondary outcomes, we performed sensitivity analyses
on the per-protocol population (full data set at week 18) and
on the population enrolled in the trial before and after the
final trial registration was approved (ie, midway), as well as
with missing data handled using multiple imputation. To
explore whether the secondary outcomes were highly
correlated and somewhat redundant with the primary out-
come, we calculated the Spearman correlation coefficients
for all change scores pairwise, in each intervention group
separately.
For the exploratory outcomes, unadjusted differences in
mean changes with 95% CIs were estimated for the continu-
ous outcomes, and unadjusted risk ratios with 95% CIs were
estimated for the dichotomous outcomes. All the statistical
tests were performed 2-sided with α = .05. The key second-
ary outcomes were analyzed in a hierarchical fixed sequence
with reporting of P values and claims of statistical signifi-
cance until 1 of the analyses failed.35 All of the analyses were
performed in SAS Studio (SAS Institute, Inc) and R, version 3.6.1




As illustrated in Figure 1, from September 7, 2017, to Decem-
ber 18, 2018, 573 youths were screened for eligibility, and
396 were randomly assigned to MMM (n = 197) or MAU
(n = 199) in the Educational-Psychological Advisory Ser-
vices of 4 Danish municipalities. The baseline group charac-
teristics were similar (Table 1). The youths’ mean (SD) age
was 10.3 (2.4) years; 190 (48.0%) were girls and 206 (52.0%)
were boys. Anxiety was the most common top problem (231
[58.3%]), followed by behavioral problems (101 [25.5%]) and
depression (64 [16.2%]). The mean (SD) parent-reported
SDQ Impact score was 4.16 (2.39), corresponding to
moderate impact in 4 of 5 domains. Three hundred seven-
teen youths (80.1%) fulfilled the diagnostic criteria for at
least 1 DSM-IV or DSM-5 mental disorder, and 102 (25.8%)
had comorbid disorders across domains (eg, anxiety and
depression).
Follow-up data for all outcomes were available by
August 28, 2019. The 197 youths allocated to MMM received
a mean (SD) 11.0 (2.6) therapy sessions (range, 0-13), and 175
(88.8%) received a full dose of 9 to 13 sessions. There were
no significant differences in the proportion of youths who
received 9 to 13 sessions among the 3 top-problem groups
(104 [91.2%] of 114 with anxiety, 27 [87.1%] of 31 with
depressive symptoms, and 44 [84.6%] of 52 with behavioral
problems; P = .43) and among the 4 municipalities (34
[91.9%] of 37 in Helsingør, 50 [86.2%] of 58 in Holstebro, 51
[87.9%] of 58 in Næstved, and 40 [90.9%] of 44 in Vording-
borg; P = .80). The therapy was provided at school or an
office nearby. A post hoc examination of the correlation
between the number of sessions and the primary outcome
showed a significant correlation (Spearman correlation coef-
ficient, −0.151; P = .045 [n = 177]), suggesting an association
between number of sessions and reduction of SDQ Impact
scores (eFigure 4 in Supplement 2). The 199 youths allo-
cated to MAU received a mean (SD) of 1.6 (0.6) coordinating
visits (range, 0-2; 198 received ≥1). By week 18, 35 MAU par-
ticipants (17.6%) received individual therapy, group therapy,
and/or parental training in the municipalities. None of the
396 trial participants withdrew consent; 344 participants
(177 [89.8%] in MMM vs 167 [83.9%] in MAU; P = .08) com-
pleted the primary outcome assessment at week 18.
Outcomes
Primary Outcome
The impact of problems, measured by the parent-reported SDQ
Impact scale, improved by −2.34 from 4.12 points for MMM vs
−1.23 from 4.21 points for MAU (difference between groups,
1.10; 95% CI, 0.75-1.45; P < .001; Cohen d = 0.60) (Figure 2 and
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Table 2). Exploratory subgroup analyses showed no moder-
ating effects of age or geographical region on the primary out-
come (eTable 10 in Supplement 2).
Secondary Outcomes
The MMM intervention was evidently superior to MAU for anxi-
ety, depressive symptoms, daily functioning, school atten-
dance,andthetop-problemscore(Table2).Child-reportedphysi-
cal well-being showed no significant difference between groups
(0.52; 95% CI, −1.01 to 2.04; P = .51), and owing to the gatekeep-
ing rule (hierarchical testing), the remaining key secondary out-
comes are reported without claiming inferential significance. All
effects of MMM vs MAU were maintained at week 26 except for
school attendance (effect size, 0.22; P = .05) (Table 3). The pri-
mary and the secondary outcomes covaried weakly or moder-
ately (range, −0.030 to 0.585 in MMM and −0.096 to 0.581 in
MAU), except for strong correlations between the 2 measures of
behavioral problems (0.719 in MMM and 0.634 in MAU), indi-
cating that the secondary outcomes added value to the pri-
mary outcome (eTables 8 and 9 in Supplement 2). Responder and
remitter status were significantly higher for MMM vs MAU, in-
cluding parent-reported responses (144 of 197 [73.1%] vs 93 of
199 [46.7%]; NNT, 4; 95% CI, 3-6) and parent-reported remis-
sions (98 of 197 [49.7%] vs 56 of 199 [28.1%]; NNT, 5; 95% CI,
3-9).
Sensitivity Analyses
The inferences from all primary and key secondary outcomes
of MMM vs MAU were robust, and the estimates were largely
unchanged when multiple imputation was used at weeks 18
(eTable 3 in Supplement 2) and 26, except for child-reported
psychological well-being (eTable 4 in Supplement 2). Like-
wise, all the results were robust when analyzing only partici-
pants with complete data (eTable 5 in Supplement 2) or when
the trial population was split by date of trial registration
(eTables 6 and 7 in Supplement 2).
Harms
The proportion of participants with increased suicidal ide-
ations or negative cognitions was similar in the MMM vs
MAU groups by week 18 (20 of 151 [13.2%] vs 22 of 121
[18%.2]; P = .26) but lower by week 26 (7 of 150 [4.7%] vs 20
of 120 [16.7%]; P = .003). A small proportion of youth (20 of
173 [11.6%] vs 12 of 142 [8.5%] at week 18; 17 of 173 [9.8%] vs
14 of 140 [10.0%] at week 26) reported deterioration in the
quality of their family relationships, free time, and friend-
ships, apparently without group differences (eTable 1 in
Supplement 2). No clinician reports of adverse effects were
received during the trial, and all participants were alive
beyond August 31, 2019.
Other Outcomes
The results of the exploratory outcomes supported the pri-
mary and secondary analyses, suggesting a broad range of ben-
efits of MMM vs MAU, including reduced impact of problems in
school (teacher-reported SDQ, range, 0-6), reduced parental
stress in role functioning (Parental Stress Scale), and improved
Experience of Service Questionnaire scores (eTable 2 in
Supplement 2). The exploratory, age-restricted self-reported out-
comes showed beneficial changes in the same direction as in the
parent-reported outcomes, except for quality of family rela-
tions,freetime,andfriendshipsatweek18(dataoverlappingwith
measures of potential harm), indicating nonsignificant inter-
vention group differences in the opposite direction.
Discussion
Timely and effective interventions are urgently needed to meet
the global burden of mental health disorders among youth.1,36
Despite existence of effective treatments, most youth with
emotional/behavioral problems do not receive them.13 Barri-
ers include lack of scalable programs and infrastructures for
successful implementation of quality care.37
Transdiagnosticapproachesmayfacilitatethelarge-scaledis-
semination of evidence-based treatments for youth mental
health problems.38 In our pragmatic RCT, the transdiagnostic,
modular MMM was significantly superior to MAU in the pri-
mary outcome of parent-reported impact of problems at the end
of treatment (week 18), with a clinically meaningful between-
group difference22 and a medium Cohen effect size of 0.60. Re-
sults were robust and consistent across several prespecified sen-
sitivity analyses. Furthermore, most secondary and exploratory
outcomes, including improvement in parent-reported youth
anxieties, depressive symptoms, daily and social functioning,
school attendance, and top-problem scores, showed similar su-
periority of MMM, as did teacher-reported impact of problems.
Response (NNT, 4) and remission (NNT, 5) were significantly
more likely with MMM, and most of the favorable results were
sustained until week 26. Finally, levels of harms were low and
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MAU group
MMM group
Trajectory of least-squares mean scores over time for the impact of the child’s
mental health problems reported by the parent (Strengths and Difficulties
Questionnaire [SDQ] Impact scale score) from baseline to week 18, plus the
extended follow-up to week 26. Least-squares mean estimates were calculated
from repeated mixed-measure models for data at 0 to 18 weeks and from
analysis of covariance models for data at 26 weeks. The analyses were based on
data from the intention-to-treat population. For each group, the error bars
indicate the standard errors. MAU indicates management as usual; MMM, Mind
My Mind intervention.
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nondifferential by the end of treatment but were significantly
lower with MMM vs MAU by week 26. The lack of effect on self-
reported physical health suggests specificity of benefits for psy-
chological mental health.
The NNT of 4 for response compares well with the esti-
mated NNT of 3 for anxiety-specific CBT vs a wait list control con-
dition. The weak or moderate correlations of the primary and
secondaryoutcomesconfirmedthatthesemeasuresmappedinto
distinct yet partly overlapping outcome domains.
Our results indicate real-life benefits of the implementa-
tion of a transdiagnostic and modular CBT in a nonspecialist
setting under the hallmark conditions of a pragmatic trial.
Of note is an important treatment-development difference
between MMM and MATCH, which has shown benefits in
the Child STEPs program.15,18 The MMM intervention was
developed for use in nonspecialized, school-based care set-
tings and MATCH, for use in community mental health care
settings. Moreover, the psychologists in MMM had limited
prior experience with CBT and manualized psychotherapy,
and yet the help-seeking individuals presented with anxi-
ety, depressive symptoms, and/or behavioral problems
above the diagnostic threshold in most of the cases.
The beneficial effects of the transdiagnostic approach in
MMM may depend on the implementation model, which in-
volved an infrastructure for managing self-referrals, visita-
tion, monitoring of activities and outcomes, user feedback for
personalized treatment, video-recorded sessions, and online
supervision. Shared infrastructure has been identified as a key
to coordinating community-based youth services.39 Our re-
sults contrasted the null effects in a recent pragmatic RCT of
Table 2. Change From Baseline in Primary and Key Secondary Outcomes at 18 Weeks (ITT Population)a
Outcome measure
MMM group MAU group







SDQ Impact scale score (parent-reported)b 197 –2.34 (0.13) 198 –1.23 (0.13) –1.10 (–1.45 to –0.75) <.001 –0.60
Key secondary
Anxiety, SCAS score (parent-reported)c 197 –6.24 (0.66) 199 –1.34 (0.67) –4.90 (–6.68 to –3.12) <.001 –0.52
Depressive symptoms, MFQ score
(parent-reported)d
197 –5.82 (0.48) 199 –2.72 (0.49) –3.10 (–4.40 to –1.81) <.001 –0.45
Level of daily functioning, WFIRS score
(parent-reported)e
197 –7.56 (0.62) 199 –2.78 (0.64) –4.78 (–6.47 to –3.10) <.001 –0.54
School attendance (parent-reported)f 197 0.03 (0.01) 199 0.00 (0.01) 0.03 (0.01 to 0.06) .009 0.26
Top-problem score (parent-reported) 197 –3.08 (0.14) 199 –1.37 (0.14) –1.71 (–2.08 to –1.33) <.001 –0.87
KIDSCREEN-27 score, mean (SD), t value
(self-reported)g
Physical Well-being scale 197 3.08 (0.54) 199 2.56 (0.59) 0.52 (–1.01 to 2.04) .51 0.06
Psychological Well-being scale 197 2.74 (0.49) 199 1.03 (0.54) 1.71 (0.33 to 3.09) NC 0.24
Behavioral problems, ECBI (parent-reported)
Intensity scoreh 197 –13.68 (0.97) 199 –6.47 (1.00) –7.20 (–9.84 to –4.56) NC –0.52
Problem scorei 197 –3.62 (0.27) 199 –2.30 (0.28) –1.32 (–2.05 to –0.59) NC –0.34
Emotional and behavioral problems, SDQ
Total Difficulties score (parent-reported)j
197 –4.07 (0.24) 198 –1.93 (0.25) –2.14 (–2.79 to –1.48) NC –0.62
Responder indices, No. (%) (parent-reported)
SDQ Impact scale score ≥1-point reduction
from baseline
197 144 (73.1) 199 93 (46.7) 3.15 (2.06 to 4.81) NC 1.58
SDQ scores below inclusion cutoffk 197 98 (49.7) 199 56 (28.1) 2.59 (1.70 to 3.95) NC 1.80
Abbreviations: ECBI, Eyberg Child Behavior Inventory; ITT, intention-to-treat;
MAU, management as usual; MFQ, Mood and Feelings Questionnaire; MMM,
Mind My Mind; NC, not calculated; SCAS, Spence Children’s Anxiety Scale; SDQ,
Strengths and Difficulties Questionnaire; WFIRS, Weiss Functional Impairment
Rating Scale.
a Data presented as least-squares means (with standard error) unless otherwise
stated. The differences between groups are the difference in least-squares
means (95% CI) for the continuous outcomes and odds ratios (95% CI) for the
dichotomous outcomes. The effect sizes are standardized mean differences
for continuous outcomes and risk ratios for dichotomous outcomes.
b Scores range from 0 to 10, with higher scores indicating greater severity of
distress and impairment.
c Scores range from 0 to 114, with higher scores indicating greater severity of
anxiety.
d Scores range from 0 to 68, with higher scores indicating greater severity of
depressive symptoms.
e Scores range from 0 to 150, with higher scores indicating more functional
impairment.
f Indicates percentage of school days in the last 4 weeks (range, 0-100).
g Determined using health-related quality of life with 5 dimensions, of which we
used the Physical Well-being and Psychological Well-being scales.
h Scores range from 36 to 252, with higher scores indicating greater intensity of
behavioral problems.
i Scores range from 0 to 36, with higher scores indicating more behavioral
problems.
j Scores range from 0 to 40, with higher scores indicating greater severity of
general psychopathology.
k Indicates parent-reported SDQ Total Difficulties score of at least 14, Emotional
Problems score of at least 5, and/or Conduct Problems score of at least 3,
combined with an SDQ Impact score of at least 1.
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transdiagnostic, modular CBT vs usual care18 using low-
intensity supervision.
Strengths and Limitations
Our study has several strengths, including a large sample size;
standardized assessments; low attrition; parent-, teacher-, and
child-reported outcomes; blinded evaluators; and intention-to-
treat analyses. Limitations include nonvalidated measures of
harms, age restrictions for child-reported outcomes, and no
blinding of participants and therapists. The parents reported lim-
ited treatment activity in the MAU group, reflecting real-world
treatment conditions.
Conclusions
T h i s p r a g m at i c RC T d e m o n s t r ate d s u p e r i o r it y o f
MMM vs MAU in the community, supporting the large-scale
dissemination of flexible, modular CBT programs
in nonspec ial ist sett ings for youth w ith common
e m o t i o n a l a n d /o r b e h a v i o r a l p r o b l e m s . F u t u r e
research should establish medium- and long-term benefits
and costs of the MMM model and include clinician
observations.
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Table 3. Exploratory Outcomes: Change From Baseline at 26 Weeks (ITT Population)a
Outcome measure







SDQ Impact scale score (parent-reported)b 179 –2.54 (2.31) 157 –1.34 (2.69) –1.20 (–1.74 to –0.66) −0.48
Key secondary
Anxiety, SCAS score (parent-reported)c 178 –8.19 (13.43) 157 –1.37 (12.62) –6.82 (–9.63 to –4.01) −0.52
Depressive symptoms, MFQ score
(parent-reported)d
178 –8.01 (10.03) 156 –3.58 (10.67) –4.43 (–6.66 to –2.20) −0.43
Level of daily functioning, WFIRS score
(parent-reported)e
178 –9.12 (13.78) 155 –4.08 (12.56) –5.04 (–7.90 to –2.18) −0.38
School attendance (parent-reported)f 170 0.06 (0.23) 148 0.01 (0.18) 0.04 (–0.00 to 0.09) 0.22
Top-problem score (parent-reported) 179 –3.30 (2.49) 158 –1.80 (2.39) –1.50 (–2.03 to –0.98) −0.62
KIDSCREEN-27 score, mean (SD), t value
(self-reported)g
Physical Well-being scale 172 4.45 (10.49) 140 3.52 (10.17) 0.92 (–1.39 to 3.24) 0.09
Psychological Well-being scale 173 4.96 (9.64) 140 2.55 (10.37) 2.41 (0.18 to 4.64) 0.24
Behavioral problems, ECBI (parent-reported)
Intensity scoreh 178 –18.04 (22.78) 155 –9.37 (19.53) –8.67 (–13.28 to –4.06) −0.41
Problem scorei 178 –4.95 (6.11) 155 –2.86 (4.98) –2.09 (–3.29 to –0.89) −0.37
Emotional and behavioral problems,
SDQ Total Difficulties score (parent-reported)j
179 –5.20 (5.23) 157 –2.73 (5.27) –2.47 (–3.60 to –1.34) −0.47
Responder indices, No. (%) (parent-reported)
SDQ Impact scale score ≥1-point reduction
from baseline
197 147 (75) 199 97 (49) 1.53 (1.30 to 1.80) 1.53
SDQ scores below inclusion cutoffk 197 115 (58) 199 62 (31) 1.87 (1.48 to 2.38) 1.87
Abbreviations: ECBI, Eyberg Child Behavior Inventory; ITT, intention-to-treat;
MAU, management as usual; MFQ, Mood and Feelings Questionnaire; MMM,
Mind My Mind; SCAS, Spence Children’s Anxiety Scale; SDQ, Strengths and
Difficulties Questionnaire; WFIRS, Weiss Functional Impairment Rating Scale.
a Data are presented as mean (SD) unless otherwise stated. Differences
between groups are unadjusted differences in mean changes with
corresponding 95% CI for continuous outcomes; for dichotomous outcomes,
differences are estimated as unadjusted risk ratios with corresponding 95% CI.
Missing data are conservatively assumed to be nonresponders. Effect sizes are
calculated as Cohen standardized mean difference for continuous outcomes
and risk ratios for dichotomous outcomes. The group difference and effect
size are identical for dichotomous outcomes (ie, both reported as risk ratios).
b Scores range from 0 to 10, with higher scores indicating greater severity of
distress and impairment.
c Scores range from 0 to 114, with higher scores indicating greater severity of
anxiety.
d Scores range from 0 to 68, with higher scores indicating greater severity of
depressive symptoms.
e Scores range from 0 to 150, with higher scores indicating greater functional
impairment.
f Indicates percentage of school days in the last 4 weeks (range, 0-100).
g Determined using health-related quality of life with 5 dimensions, of which we
used the Physical Well-being and Psychological Well-being scales
h Scores range from 36 to 252, with higher scores indicating greater intensity of
behavioral problems.
i Scores range from 0 to 36, with higher scores indicating more behavioral
problems.
j Scores range from 0 to 40, with higher scores indicating greater severity of
general psychopathology.
k Indicates parent-reported SDQ Total Difficulties score of at least 14, Emotional
Problems score of at least 5, and/or Conduct Problems score of at least 3,
combined with an Impact scale score of at least 1.
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